CCS
AZN icon

Crosspoint Capital Strategies’s AstraZeneca AZN Stock Holding History

Crosspoint Capital Strategies’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-43
Closed -$6K – 168
2015
Q4 		$6K Sell
43
-172
-80% -$11.3K ﹤0.01% 770
2015
Q3 		$14K Hold
215
– – 0.02% 376
2015
Q2 		$14K Hold
215
– – ﹤0.01% 456
2015
Q1 		$15K Buy
215
+149
+226% +$10.4K 0.01% 364
2014
Q4 		$5K Hold
66
– – ﹤0.01% 582
2014
Q3 		$5K Hold
66
– – ﹤0.01% 417
2014
Q2 		$5K Hold
66
– – ﹤0.01% 439
2014
Q1 		$4K Hold
66
– – ﹤0.01% 594
2013
Q4 		$4K Buy
+66
New +$3.58K ﹤0.01% 505

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Crosspoint Capital Strategies's AZN Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of AstraZeneca (AZN) in Q1 2016, closing a stake of 43 shares — an estimated $6K sold.

Crosspoint Capital Strategies first reported a position in AZN in Q4 2013 and held it in 9 quarters. The position peaked at $15K in Q1 2015. 390 funds tracked by Wall St. Rank hold AZN as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining AstraZeneca position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 43 AstraZeneca shares in Q1 2016, an estimated $6K.
  • Crosspoint Capital Strategies first reported a position in AstraZeneca in Q4 2013 and held it in 9 quarters.
  • Crosspoint Capital Strategies's AstraZeneca position peaked at $15K in Q1 2015.
  • 390 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.